ARCYN Defense has closed its seed financing round to accelerate development of next-generation air and counter-threat defense systems designed for modern, contested battlefields. Formerly Marteos Industries, the company is advancing an edge-AI-enabled, kinetic defense platform focused on precision, resilience, and affordability at scale. ARCYN is preparing its minimum viable product for upcoming demonstrations with the U.S. Department of War and has assembled a seasoned leadership team and advisory board of senior military and space operations leaders. The company aims to redefine the economics of air defense in response to rapidly proliferating, low-cost threats. 

WASHINGTON, Feb. 18, 2026 — ARCYN Defense today announced the successful close of its seed financing round to accelerate development of its next-generation air and counter-threat defense systems.

Formerly Marteos Industries, ARCYN Defense is building on an early prototype air defense platform that leverages edge artificial intelligence, advanced sensing, and kinetic technologies to deliver affordable, high-precision protection against emerging battlefield threats. The company’s minimum viable product is currently under development and preparing to participate in several upcoming demonstrations with the U.S. Department of War (DOW).

ARCYN Defense also announced the appointment of its management team, led by Dr. Aaron Poynton, Chief Executive Officer, Dr. Fazel Farahmand, Chief Technology Officer, and Lou Schiliro, Head of Operations.

In addition, the company confirmed the formation of a distinguished advisory board that includes Major General Brook Leonard (Ret.), former Deputy Commander and Director of Operations for Combined Task Force–Space Operations and former Chief of Staff to U.S. Space Command; Lieutenant General Eric Wesley (Ret.), former Deputy Commanding General of U.S. Army Futures Command and former Commanding General at Fort Benning, Georgia; and Colonel Terry Virts (Ret.), U.S. Air Force, former NASA astronaut and commander of the International Space Station.

ARCYN Defense is focused on redefining the economics of modern defense by delivering systems designed for speed, adaptability, and scale in contested environments where low-cost, proliferated threats are reshaping the character of warfare.

“Our mission is to build defense systems aligned with today’s operational realities,” Poynton said. “ARCYN is focused on precision, resilience, and affordability at a scale that enables real deterrence.”

About ARCYN Defense
 ARCYN Defense is a U.S.-based defense technology company developing next-generation air and counter-threat defense systems powered by edge AI and advanced kinetic technologies, purpose-built for modern and future operational environments.

For media inquiries, contact:
Aaron Poynton
443.643.8811
[email protected]

SOURCE ARCYN Defense

Valuation doubles and annual recurring revenue grows nearly four times, driven by Fortune 1000 adoption

SANTA CLARA, Calif., Feb. 18, 2026 — Selector, a leader in AI-driven observability and network intelligence, today announced a $32 million funding round, doubling the company’s valuation to $375 million. The new round was led by AVP alongside Ansa Capital, Two Bear Capital, Sinewave Ventures, Singtel Innov8 and other existing investors. The investment will be used to accelerate AI innovation, product development, global go-to-market expansion, and customer success.

The capital infusion follows last month’s announcement of eight foundational U.S. patents, covering causal inference, large language model (LLM) training, AI-powered correlation, predictive maintenance, and network path intelligence. By horizontally correlating data across the entire stack, the Selector AI solution eliminates the silos of traditional vertical tools to provide a single pane of glass for true root-cause analysis, offering a flexible architecture that adapts to enterprise workflows rather than forcing them into rigid, vendor-defined platforms.

The company has seen strong momentum in 2025, marked by sustained enterprise growth, increased global adoption, and major product innovation, with key milestones such as:

• Cumulative annual recurring revenue (ARR) reached 230% of 2024 levels, marking the fourth year the company doubled ARR
• New ARR booked reached 370% of 2024, driven by accelerating enterprise demand
• Added three new Fortune 20 customers across manufacturing and healthcare; approximately 80% of customers are now Fortune 1000 organizations
• Continued global expansion through major cloud marketplaces and regional partnerships
• Expanded into the Japanese market, establishing new strategic partnerships and onboarding the company’s first Japanese enterprise customers

“Selector’s ability to deliver consistent strong growth while serving the world’s most complex Fortune 20 networks is a testament to the team’s execution and the mission-critical nature of the platform,” said Alex Scherbakovsky, general partner at AVP. “By providing one platform and one shared operational view, Selector helps enterprises understand and troubleshoot complex infrastructure challenges in real time. We are excited to partner with Selector to support the company’s international expansion and continued product innovation.”

“The increased adoption by Fortune 20 and Fortune 1000 organizations underscores the trust customers are placing in Selector,” said Kannan Kothandaraman, CEO of Selector. “Enterprises are moving away from fragmented monitoring tools toward platforms that deliver intelligence, context, and automation at scale, and our rapid customer expansion validates our efforts to help them navigate this transition and modernize their operations.”

Selector also announced plans to release its next generation ChatOps capabilities providing a more powerful Agentic ChatOps, designed to support multi-turn reasoning, iterative investigation, and deeper operational context.

About Selector

Selector delivers an AI-powered observability and network intelligence platform that unifies data, correlation, and automation across domains. By combining large language models, knowledge graphs, and causal reasoning, Selector enables teams to detect, diagnose, and resolve issues faster. Leading telecommunications providers, cloud service providers, and global enterprises rely on Selector to reduce MTTR, prevent outages, and accelerate transformation.

Selector is backed by leading investors, including Ansa Capital, Atlantic Bridge Ventures, AT&T Ventures, AVP, Bell Ventures, Comcast Ventures, Hyperlink Ventures, Two Bear Capital, Sinewave Ventures, and Singtel Innov8.

Media Contact:

Stephen Ochs

[email protected]

Georgiana Comsa

Silicon Valley PR

[email protected]

SOURCE Selector

The Series E doubles Vestwell’s valuation as the company surpasses 2 million active savers, $50 billion in assets, and $200 million in annual recurring revenue

NEW YORK, Feb. 18, 2026 — Vestwell, the infrastructure platform powering America’s modern savings economy, has raised $385 million in Series E funding. The round was led by Blue Owl Capital and Sixth Street Growth, with participation from new and existing investors, including Neuberger Berman, SLW, Morgan Stanley, Franklin Templeton, TIAA Ventures, and HarbourVest. JPMorgan was placement agent and structuring agent for Vestwell in connection with the financing.

The financing doubles Vestwell’s valuation since its 2023 Series D and brings total capital raised to $660 million. Vestwell has surpassed $200 million in annual recurring revenue and continues to grow profitably. The financing reflects investor confidence in Vestwell’s role as the infrastructure layer for how Americans save.

Vestwell’s growth comes at a critical time, as millions of Americans remain financially vulnerable and under-prepared for emergencies and major life milestones such as college education and retirement.

What This Capital Unlocks

Vestwell is expanding its distribution across all channels where income is earned and benefits are delivered, while advancing intelligent, AI data-driven experiences and extending savings pathways beyond retirement. By embedding savings more deeply into payroll, benefits platforms, financial institutions, and government-led public programs, Vestwell’s platform reaches workers and families where saving actually happens.

The company is also expanding access to more sophisticated, professionally managed investment solutions. These capabilities—historically reserved for larger, institutional plans—move beyond basic, age-based defaults to incorporate a broader set of personalized factors tied to long-term retirement income goals. As a result, more employers and savers can benefit from a tailored, holistic investment approach using Vestwell’s award-winning technology.

Ongoing investment in AI-native capabilities personalizes guidance, automates administration, and surfaces actionable insights for savers and their employers. Together, these advances enable saving to start earlier, adapt more holistically to life’s needs, and operate as a connected, end-to-end experience.

“We’re focused on an ambitious goal to close the $50 trillion savings gap in America,” said Aaron Schumm, founder and CEO of Vestwell. “This capital allows us to move faster on the work that matters most. It reflects strong confidence from leading investors in our unified savings platform and our ability to scale across payroll, partners, and products. We’re deepening the intelligence behind the platform and expanding access beyond retirement so more people can save in ways that best fit their lives.”

A New Approach to Saving

For decades, saving in America has been fragmented. Separate systems for retirement, emergencies, education, disability, and long-term goals each had their own rules, vendors, and barriers to participation.

Today, Vestwell supports more than 2 million active savers and administers over $50 billion in assets through employers, financial institutions, advisors, payroll providers, and government agencies nationwide. Its innovations lower barriers to participation, deliver measurable outcomes, and expand access to modern savings across income levels, languages, and communities.

A secure retirement remains foundational, but achieving that goal requires a broader approach to saving that starts with the first dollar. Vestwell’s platform already powers a broad set of savings pathways—from workplace emergency savings and programs that seed early wealth for college savings and student debt solutions, to ABLE accounts that protect benefits for people with disabilities—delivered through a single, modern infrastructure layer.

“Vestwell has built a resilient platform with strong underlying economics and a clear path for continued expansion,” said Tim DeGrange, a principal of Blue Owl Capital. “The company’s ability to scale profitably while broadening both its product offering and distribution reflects the durability of its model and the strength of its execution. Vestwell is building long-term infrastructure for the savings ecosystem, enabled for today’s age of AI.”

As adoption accelerates across both the private and public sectors, Vestwell has emerged as the connective layer across how saving works in the U.S.

At Scale Today

• More than 2 million active savers using Vestwell-powered programs
• More than $50 billion in assets administered across workplace, institutional, and government channels
• Nearly 30,000 plans added through the Accrue 401k acquisition
• More than 40 government programs leveraging Vestwell infrastructure
• Multilingual experiences across more than 20 languages and AI-powered assistance delivering real-time, personalized support

“Vestwell’s platform has reached an important inflection point, combining innovation and scale with the flexibility to support a broad and evolving set of savings use cases,” said Alex Goodman, principal at Sixth Street Growth. “As demand for integrated savings solutions accelerates across employers, advisors, and partners, we believe Vestwell is well-positioned to build on its momentum and expand its impact over time.”

“The Vestwell team has built a leading savings platform that is extending its reach across major payroll providers with the Accrue 401k acquisition,” said Michael Noryko, managing director at SLW. “Aaron Schumm, Dave Sheen and the leadership team at Vestwell have a long track record of building value with successful acquisitions. They are well positioned to be the backbone for the modern savings economy and we look forward to extending our partnership.”

About Vestwell
Vestwell is the backbone of the modern savings economy. Vestwell is a financial technology company that makes it easier for more Americans to save for life’s most important moments—from retirement to education and healthcare. Founded in 2016, Vestwell’s platform removes traditional barriers to saving, making it accessible, efficient, and approachable for everyone.

Vestwell provides a comprehensive suite of workplace savings solutions, including retirement plans, student loan repayment benefits, and specialized accounts for education, emergencies, and disability savings.

Trusted by financial advisers, employers, payroll providers, financial institutions, and government agencies. With a commitment to closing the savings gap and fostering a secure financial future for all, Vestwell provides the accessible savings technology everyone deserves.

For more information, visit www.vestwell.com.

About Blue Owl Capital Inc.
Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives^®. With over $307 billion in assets under management as of December 31, 2025, we invest across three multi-strategy platforms: Credit, Real Assets and GP Strategic Capital. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation.

Together with approximately 1,365 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com or LinkedIn: www.linkedin.com/company/blue-owl-capital

About Sixth Street Growth
Sixth Street Growth provides growth equity and bespoke capital solutions to mid- and late-stage technology companies. Sixth Street Growth is the dedicated growth investing platform of Sixth Street, a leading global investment firm with over $125 billion in assets under management and committed capital. Sixth Street has invested over $10 billion in more than 70 companies through its Growth franchise since inception. For more information, and additional disclosures, visit www.sixthstreet.com/growth, and follow Sixth Street on LinkedIn.

About SLW
SLW focuses on providing flexible expansion capital to later-stage growth companies in the technology and technology-enabled industries. For more information about Silver Lake Waterman, please visit www.slw.vc.

SOURCE Vestwell

Investment Led by Edge Medical Ventures to Accelerate U.S. Commercial Growth and Clinical Adoption of FDA-Cleared LibAirty™ System

OR YEHUDA, Israel and JERSEY CITY, N.J., Feb. 18, 2026 — Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ Airway Clearance System, today announced it has closed an oversubscribed $5 million funding round. The investment, led by Edge Medical Ventures with participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG), and angel investors, will accelerate U.S. commercial expansion, support ongoing clinical research and product development, and broaden patient access to LibAirty™.

For millions living with chronic lung conditions, airway clearance is essential to managing symptoms, preventing infections, and slowing disease progression. The LibAirty™ system delivers this vital therapy through a daily home treatment that has shown the ability to clear twice as much sputum as conventional therapies with enhanced user comfort and satisfaction. Since its commercial launch in late 2025, LibAirty™ has received an enthusiastic response from both patients and clinicians, demonstrating immediate impact on daily condition management.

“This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health,” said Anat Shani, CEO of Synchrony Medical. “Supported by our exceptional investors and new board members, we’re well positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation.”

In conjunction with the funding, Synchrony announced the appointment of Kevin Kotler, General Partner of Broadfin Holdings, and Elad Duschak, Strategic Advisor to CBG for Healthcare, to the company’s Board of Directors, strengthening strategic oversight as the company enters its next phase of growth.

“The LibAirty™ System, with its proven clinical advantage, is poised to disrupt a market with high demand and strong growth,” said Kevin Kotler, General Partner of Broadfin Holdings. “We look forward to working with the team to scale nationwide and create meaningful value for both patients and shareholders.”

Synchrony will continue to expand its U.S. team and operations from its Jersey City headquarters. The financing includes $1M funding from the NJEDA through the New Jersey Innovation Evergreen Fund (NJIEF)’s co-investment with Edge Medical Ventures, further supporting the company’s growth and presence in the state.

“Synchrony exemplifies the type of innovation we seek to support, addressing an unmet clinical need through strong clinical foundations and a clear path to transforming patient care,” said Shai Policker, Chairman of Synchrony and Managing Partner at Edge Medical Ventures. “This demonstrates how Edge’s transatlantic presence, combined with the company’s proven execution capabilities, can establish a new standard of care and bring it to market.”

“As partners of EdgeLabs (formerly MEDX Xelerator), we are proud to support Synchrony from its early stages of development and witness its remarkable progress,” said Mr. Vincent Tchenguiz, Chairman of Consensus Business Group. “We are pleased to continue supporting this important, high-impact medical innovation and make it more widely available for patients.”

About Synchrony Medical 

Synchrony Medical is a respiratory care technology company dedicated to providing advanced at-home airway clearance therapy. The company’s FDA-cleared LibAirty™ Airway Clearance System transforms respiratory therapy into an easy-to-manage daily routine that patients can perform independently at home, setting a new standard of care for those living with chronic lung disease. Developed in collaboration with leading pulmonologists at Sheba Medical Center, LibAirty™ was founded through Edge Medical Ventures’ EdgeLabs (formerly MEDX Xelerator) and is supported by the Israel Innovation Authority. Synchrony Medical is headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel. For more information, visit https://libairty.health.

Media Contact:
Aviva Sapir
Number 10 Strategies
[email protected]

SOURCE Synchrony Medical

• HUMAIN invested $3 billion in xAI’s Series E round just prior to its acquisition by SpaceX, positioning itself at a pivotal moment of platform-scale expansion and integration
• As a result of the transaction, HUMAIN became a significant minority shareholder, with its xAI holdings converted into SpaceX shares
• The investment builds on HUMAIN and xAI’s 500MW AI infrastructure partnership in Saudi Arabia, reinforcing HUMAIN’s role as both a strategic development partner and a leading global investor in frontier AI technologies

RIYADH, Saudi Arabia, Feb. 18, 2026 — HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today announced a $3 billion strategic investment in xAI as part of the company’s Series E financing round. The transaction represents a significant, end-to-end capital deployment for HUMAIN, reflecting continued momentum in its long-term investment strategy focused on category-defining technology platforms.

The investment comes at a highly compelling inflection point for xAI, preceding its acquisition by SpaceX in early February. The combination of xAI’s advanced artificial intelligence capabilities with SpaceX’s scale, infrastructure, and mission-driven engineering creates a uniquely positioned platform for accelerated growth, deep technological integration, and long-term value creation.

As a result of the Series E transaction, HUMAIN became a significant minority shareholder in xAI, with its holdings subsequently converted into shares in SpaceX. The transaction creates a solid platform for HUMAIN’s exposure to long-term equity upside, reflecting participation in xAI’s final financing round ahead of the merger.

“This investment reflects HUMAIN’s conviction in transformational AI and our ability to deploy meaningful capital behind exceptional opportunities where long-term vision, technical excellence, and execution converge,” said Tareq Amin, CEO of HUMAIN. “xAI’s trajectory, further strengthened by its acquisition by SpaceX, one of the largest technology mergers on record, represents the kind of high-impact platform we seek to support with significant capital.”

HUMAIN’s participation in the Series E round reinforces its role as a scaled, long-term strategic investor capable of supporting companies across multiple stages of growth, while delivering full-stack AI capabilities across four core areas: next-generation data centers; high-performance infrastructure and cloud platforms; advanced AI models; and transformative AI solutions.

The investment builds on the large-scale partnership announced in November 2025 at the U.S.-Saudi Investment Forum, under which HUMAIN and xAI committed to jointly develop more than 500MW of next-generation AI data center and compute infrastructure and to deploy xAI’s Grok models in Saudi Arabia. Together, these initiatives deepen long-term alignment and extend HUMAIN’s role from strategic partner to leading global shareholder in xAI.

Looking ahead, HUMAIN’s strategy includes the pursuit of additional investments across artificial intelligence, frontier technologies, and critical infrastructure.

About HUMAIN

HUMAIN, a PIF company, is a global artificial intelligence company delivering full-stack AI capabilities across four core areas: next-generation data centers; hyper-performance infrastructure and cloud platforms; advanced AI models, including some of the world’s most advanced Arabic large language models developed in the Arab world; and transformative AI solutions that combine deep sector insight with real-world execution.

HUMAIN’s end-to-end model serves both public and private sector organizations, unlocking value across industries, driving digital transformation, and strengthening capabilities through human–AI collaboration. With a growing portfolio of sector-specific AI products and a core mission focused on intellectual property development and global talent leadership, HUMAIN is engineered for international competitiveness and technological excellence.

Forward-Looking Statement:

This press release may contain forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to various risks and uncertainties. HUMAIN undertakes no obligation to update these statements.

Photo: https://mma.prnewswire.com/media/2915934/HUMAIN.jpg
Logo: https://mma.prnewswire.com/media/2915933/HUMAIN_Logo.jpg

Media Inquiries:
For further details about HUMAIN, please visit humain.com.
For Media inquiries, please contact:
Hana Nemec, Head of Communications & PR
[email protected]
Follow HUMAIN on: X | LinkedIn

SOURCE HUMAIN

Funding will enable Rainfall Health to enhance AI-enabled solutions for the 742 TEAM-mandated health systems in new value-based reimbursement era

SAN FRANCISCO, Feb. 18, 2026 — Rainfall Health, an AI-driven compliance and reimbursement platform for hospitals and medical groups, today announced it has closed on a $15 million Series A funding round. The company will lean on this investment to build out its AI teams and build a world-class customer support team, who will support the hospitals impacted by the Transforming Episode Accountability Model (TEAM), which launched on January 1, 2026.

This new CMS mandate incentivizes hospitals and health systems to deliver on quality outcomes associated with the five highest-spend surgical procedures: lower extremity joint replacement, spinal fusion, coronary artery bypass graft, major bowel procedures, and hip/femur fracture treatment. By complying with the quality metrics, hospitals now stand to gain 20% in increased revenue from existing lines of service, yielding more than $100 million in new revenue per Health System.

“Hospitals have a tremendous opportunity to increase their revenues by delivering high-quality post-acute care that includes consistent check-ins, clear patient instructions, and clinician follow-ups,” said Eddie Qureshi, CEO and Founder of Rainfall Health. “By building out our AI and implementation teams, we will ensure our partners take advantage of this opportunity with CMS while delivering a consistent patient experience. This funding is a vital step for Rainfall as we continue to build the country’s first recognized standard for outcome-based care.”

This Series A investment was led by Two Bear Capital, along with support from other notable investors.

“Building an AI platform for hospitals and health systems to more effectively collect, standardize, and report on patient outcomes will forever change the way they track reimbursement,” said Mark Adams PhD, Partner at Two Bear Capital. “It will create unique new value for patients, providers, and an amazing portfolio business for Two Bear Capital. We’re excited to see Rainfall grow as its platform is deployed across the growing list of US hospitals that will need to deliver on the in-depth infrastructure requirements mandated by TEAM.”

Rainfall Health is the only product on the market that acts as a single blueprint for navigating compliance in this new era of reimbursement. Rather than seeing compliance rules as a downside for hospitals, Rainfall Health is driving towards the opportunity that exists for providers across the country to invest further into a new standard of care and access for their patients. The platform, which is already implemented across several impacted medical groups and hospitals, is built on increased healthcare access, hospital workflow efficiency, and regulatory compliance – all with the goal of improving patient outcomes.

“Rainfall is enabling providers across the country to connect with patients and deliver on their goals at a scale in which the industry hasn’t seen before,” said David Shulkin M.D., the Ninth Secretary of the US Department of Veterans Affairs and Chair of the RAIN Advisory Committee. “Eddie and his team’s commitment to moving the value-based care needle and supporting hospitals in aligning financial incentives with quality patient outcomes is refreshing to see. This funding round will allow Rainfall to accelerate their implementations as TEAM requirements begin to take hold this year.”

Rainfall Health remains committed to its original mission of using AI to ensure patients in any and all geographic areas have access to quality medical care. The platform will continue to play a key role in doing this across the country, as the outcome-based care model outlined in TEAM will accelerate the industry’s adoption of a more value-based approach in 2026 and beyond.

About Rainfall Health:
Rainfall Health is an AI-driven compliance and reimbursement platform that helps hospitals and medical groups navigate new value-based care models such as CMS’s TEAM model, ensuring they deliver on vital case management and care delivery goals. The company is shaping a new national standard for mandated care-model compliance through the RAIN Compliant^™ designation — a verifiable, AI-enabled framework adopted by hospitals, payers, and clinical partners impacted by the January 1, 2026 TEAM launch. Rainfall works with health system executives, physician groups, and post-acute partners to automate complex regulatory requirements, improve care-quality performance, and unlock new Medicare revenue streams. Follow Rainfall Health on LinkedIn and Twitter.

Media Contact
Will Pegler
+1 (203) 962-5694
[email protected]

SOURCE Rainfall Health

• SGT Capital Artificial Intelligence (AI) Co-Investment Fund Closes 25% Oversubscribed
• SGT Capital commits to invest in Artificial Intelligence as an expansion of Data Analytics & Cybersecurity
• SGT Capital Partners Joseph Pacini, Carsten Geyer, Dino Steinborn, Marcel Normann and Marianne Rajic applaud recent fundraising success

ZUG, Switzerland, Feb. 18, 2026 — SGT Capital announces the successful closing of its SGT Capital Artificial Intelligence (AI) Co-Investment Fund, which was 25% oversubscribed.  This fund strengthens SGT Capital’s strategy to invest in market-leading data analytic, cybersecurity and med-tech companies.  The SGT Capital AI Co-Investment Fund builds on SGT Capital’s established track record in technology-enabled sectors and reflects growing institutional investor demand for exposure to transformative AI-driven business models. 

SGT Capital Partners Joseph Pacini, Carsten Geyer, Dino Steinborn, Dr Marcel Normann, and Marianne Rajic applaud the strong investor demand and the successful fundraising outcome, stating:

“Artificial Intelligence (AI) is the key driver of growth for the global economy, and every company will either deploy AI or face disruption by it. This success underscores strong investor conviction in SGT Capital’s disciplined approach to backing market leading businesses and producing top decile returns.  AI is now a permanent feature of the global economy and SGT Capital is uniquely positioned to identify and support category-defining AI businesses, combining deep sector expertise with a disciplined investment approach.  The oversubscription of this fund reflects investor confidence in SGT Capital’s strategy, team, and track record.  We are grateful for the trust our investors have placed in us and look forward to deploying capital into high-conviction opportunities that drive technological transformation and long-term value creation.”

The SGT Capital AI Co-Investment Fund will focus on investments in scalable technology platforms across North America, Europe, and selected global markets. SGT Capital will leverage its operational expertise and global network to support portfolio companies in scaling revenue, expanding internationally, and strengthening governance and cybersecurity frameworks.

About SGT Capital

SGT Capital Group is a global private equity firm that generates top decile performance for its investors by investing in market leading businesses and expanding their international growth. With offices and portfolio company presence in London (United Kingdom), Zug (Switzerland), Frankfurt (Germany), Dubai (UAE), Silicon Valley (CA, USA), and Singapore, SGT Capital is led by Joseph Pacini, Carsten Geyer, Dr Marcel Normann, Marianne Rajic and Jens Dino Steinborn.

SOURCE SGT Capital

One of Texas’ largest angel rounds bets on scaling expertise as manufacturing’s skills gap widens

AUSTIN, Texas, Feb. 18, 2026 — Circuit, an Austin-based company building an AI platform for manufacturing and service organizations, today announced it has raised $30 million from individual investors. The funding comes as manufacturers face growing market and product complexity while a wave of retirements takes decades of expertise out the door.

“The work is getting harder and the people who know how to do it are leaving,” said Tyson Tuttle, co-founder and CEO of Circuit. “Products are more complex, tools are changing, and U.S. manufacturers are being asked to produce more with fewer experienced hands. Circuit exists to make sure expertise scales with the business.”

Manufacturing and service teams make hundreds of high-stakes decisions every day: configuring equipment, building quotes, guiding installations, and troubleshooting issues. The knowledge behind those decisions lives across scattered documentation and legacy systems – but more often in the heads of the people who’ve done the work for decades. Deloitte and The Manufacturing Institute estimate that expertise drain could leave as many as 1.9 million manufacturing jobs unfilled by 2033.

“In a market crowded with general-purpose AI, it matters that Circuit actually understands manufacturing and service workflows – and how to measure success,” said Tony Bender, executive and advisor at Culligan. “They’re turning our years of product documents and operational know-how into guided execution our teams and dealers can rely on.”

Circuit turns that documentation – including complex visuals like technical manuals, schematics, CAD files, and exploded views – into actionable workflows that help teams configure, quote, and troubleshoot with confidence. The platform plugs into ERPs, quoting tools, and CRMs, pulling documentation from where it already lives. Teams input job requirements or field conditions in plain language. Circuit then layers on proprietary reasoning that interprets configuration logic, compatibility rules, and technical dependencies.

Leading manufacturers and product-driven service organizations – such as Culligan and Four Hands – are already seeing results: faster quotes, fewer support errors, and new hires up to speed in weeks instead of months.

The round includes backing from business leaders and experienced company builders who have built and scaled multi-billion-dollar organizations. Investors include Jim Breyer, Charlie Amato, Lew Cirne, Niccolo De Masi, Tom Long, Gary Petersen, Gary Rieschel, and Craig Robins.

Circuit was founded by Silicon Labs veterans, including former CEO Tyson Tuttle, who bring decades of experience building and shipping products in manufacturing and industrial environments. That firsthand perspective shaped both the platform and Circuit’s approach to partnering with customers – integrating AI into the workflows their teams rely on every day. The new funding will support continued product development, expanded customer deployments, and hiring across engineering and go-to-market teams.

By embedding trusted guidance into everyday workflows, Circuit helps manufacturers move faster, reduce errors, and deliver more consistent execution.

About Circuit
Circuit is purpose-built AI for manufacturing and service organizations. The platform turns technical documentation into an intelligent engine that guides teams through business-critical workflows like quoting, field service, and customer support. Learn more at circuit.ai.

Media Contact
Vanessa Blankenship
Sun PR
Email: [email protected]
Phone: 941-228-2488

SOURCE Circuit

• Round led by Heran Partners and joined by Clave Capital, Inveready and Bio&Tech Smart Capital
• Financing will enable Pharmacelera to build ongoing relationships with major pharm and biotech customers in the US
• Pharmacelera’s platform scours vast chemical ‘exaSpace’ accurately for novel molecules

BARCELONA, Spain, Feb. 18, 2026 — Pharmacelera, a deep tech company applying Quantum Mechanics and Artificial Intelligence to revolutionize drug discovery, has closed a €6 million investment round to accelerate its expansion in the United States and grow the capabilities of its proprietary platform.

Utilizing its proprietary Quantum Mechanics and Artificial Intelligence (“QaiM”) algorithms, Pharmacelera is revolutionizing drug discovery by finding novel and diverse molecular candidates across the vast chemical “exaSpace” with unprecedented speed, efficiency and accuracy. It can generate molecules that are up to 10 times better, 75,000 times faster, than traditional AI-led drug discovery approaches. Its technology can be applied to small molecules and small peptides in all stages of drug discovery – from hit identification, through hit-to-lead, to lead optimization.

This investment round will help Pharmacelera grow further and faster – firstly, by establishing a permanent team in the U.S., and secondly, by enabling the Company to expand the technical capabilities of its unique QaiM drug discovery engine in key growth areas.

The round was led by Heran Partners, a leading life sciences investor, and joined by Clave Capital, a long-standing tech transfer investor; Inveready, a Spanish alternative asset manager with a dedicated life sciences strategy; and Bio&Tech Smart Capital, a specialist investor in healthtech and science-based innovation.

Pharmacelera has already participated in more than 100 projects to date, including several notable successes in GPCRs. It has won repeat business from customers in both Europe and the U.S., including three big pharma companies and numerous highly-regarded biotechs.

Enric Gibert, Chief Executive Officer of Pharmacelera, said: “The first wave of AI-powered drug discovery promised a lot but delivered comparatively little. Pharmacelera is changing the picture, by coupling AI with quantum-based simulations to leverage the exaSpace – the vast, undiscovered universe of trillions of molecules – to find highly novel drug candidates that are up to 10 times better, using a process that’s up to 75,000 times faster than traditional AI-led approaches.”

He continued: “The backing of these leading investors, who have a deep understanding of drug discovery, is a strong validation of our revolutionary technology. The funding will enable us to establish a team in the U.S. – a natural next step to continue strengthening our relationships with large pharmaceutical and biotech companies on both the East and West coasts. It will also help us to greatly widen the capabilities of our QaiM engine.”

Raf Roelands, Partner at Heran Partners and new member of Pharmacelera’s Board of Directors, said: “By combining physics-based algorithms with machine learning, Pharmacelera enables the design of molecular candidates for novel targets and modes of action with a higher probability of success. We have a high conviction in this company, which was reinforced through direct discussions with its customers, including leading pharmaceutical companies, who have already experienced the significant impact of its technology.”

The funding round follows the signing of a strategic alliance between Pharmacelera and Silicon Valley company igniter General Inception (GI) in 2023, in which Pharmacelera became GI’s AI drug discovery strategic partner. Venkat Reddy, GI’s Chief Scientific Officer, sits on Pharmacelera’s Board of Directors. Since then, Pharmacelera’s technology has strengthened the intellectual property of several of GI’s portfolio companies.

About Pharmacelera

Pharmacelera is a deep tech computational drug discovery company applying its advanced 3D Quantum Mechanics and Artificial Intelligence (“QaiM”) engine to explore the vast chemical “exaspace” – which potentially comprises trillions of molecules – with unprecedented speed, efficiency and accuracy. This engine can significantly outperform traditional methods in its ability to identify structurally diverse, novel, and synthesizable compounds. Using this technology, the Company’s world class, cross-disciplinary team has already participated in more than 100 projects. Pharmacelera’s diversified and scalable business model has attracted recurrent customers including several big pharma firms and many prominent biotechs. Founded by AI engineers, drug hunters from industry and top academic profiles, its founders have co-authored more than 500 publications and hold more than 50 patents on technology and drug discovery. It is backed by Heran Partners, Clave Capital, Inveready and Bio&Tech Smart Capital and based at the Parc Científic de Barcelona, one of Europe’s premiere life science hubs. For more information, please visit https://pharmacelera.com/ 

About Heran Partners

Heran Partners is a specialist venture capital investor committed to creating transformative impact within the life sciences and healthcare industry. It is a Belgium-based investment fund driven by a dedicated team with strong scientific and entrepreneurial backgrounds. It provides venture and growth capital accompanied by a strong network, expertise and mentorship to start-ups and scale-ups with a solid technology platform and strong market potential.

Heran’s investment philosophy centers on addressing emerging health challenges such as an ageing population, the surge in chronic diseases, and associated increases in healthcare costs. Heran believes in harnessing the revolutionary potential of technology, science, and data to meet these challenges head-on. It focusses on solutions for unmet needs in the market. For more information, please visit https://www.heranpartners.com/ 

About Clave Capital

Clave Capital is an independent alternative asset management firm specialized in innovative projects and industrial SMEs. The firm has extensive experience in creating business value from scientific research results, with more than 20 years of expertise in investing, building, and supporting technology projects from their early stages, with a clear focus on technology transfer. Currently, the firm manages €173 million, with a highlight being Clave Innohealth F.C.R., a €50 million fund specialized in medical technologies and promoted with the support of CDTI Innvierte and several private investors linked to the healthcare sector. For more information, please visit https://clave.capital/ 

About Inveready

Inveready is a leading financial services firm specialized in Alternative Assets, Wealth Management, and Investment Funds. Founded in 2008 as a venture capital fund, Inveready has evolved into one of the most active investment firms for small and medium-sized enterprises in Spain, currently managing over €2.4 billion.

The financial group organizes its services into three main business lines: Alternative Assets, which includes various direct investment strategies (Venture Capital, Life Sciences Venture Debt, Strategic Public Equity, Private Equity, and Infrastructure); Wealth Management, which advises clients across a range of high-value products and services; and Investment Funds, investing in small-cap equities with a value investing approach through its management company True Value.

With a team of 60 employees, Inveready is headquartered in San Sebastián, with offices in Barcelona and Madrid. The firm has been recognized as “Best Venture Capital Firm” by SpainCap in 2017 and “Best European Venture Debt Fund” by Preqin in 2023, among other awards. For more information, please visit https://inveready.com/ 

About Bio&Tech Smart Capital

Bio&Tech Smart Capital, FCRE is an early-stage venture capital fund based in Santiago de Compostela, Spain, focused on investing in life sciences, healthtech and science-driven technology companies. The fund is managed by Noso Capital and is deeply connected to Galicia’s growing innovation ecosystem, combining strong regional roots with an active investment focus across Spain.

The fund was created with the mission of translating scientific knowledge into scalable, high-potential businesses, supporting founders at Seed and Series A stages. Bio&Tech Smart Capital is led by a team combining venture capital experience, scientific research and entrepreneurship, backing differentiated technologies with clear and meaningful applications in healthcare. For more information, please visit https://biotechsmartcapital.com/, https://nosocapital.com/es-es/index 

About General Inception

General Inception (GI) is pioneering company creation as an Igniter company. General Inception partners with extraordinary scientific founders at the inception of their journey to efficiently translate their groundbreaking innovations into transformational companies that address humanity’s grand challenges. As a business co-founder, GI brings together domain and functional expertise, executive talent, infrastructure and development resources, and capital to ignite, nurture and scale the company journey. GI is backed by leading venture capital firms Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners. For more information, please visit https://www.generalinception.com/

SOURCE Pharmacelera